Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Gilead Sciences |
---|---|
Information provided by: | Gilead Sciences |
ClinicalTrials.gov Identifier: | NCT00743340 |
The purpose of this study is to provide current FTC-203 study participants in South Africa with continued access to the study drug, emtricitabine, following completion of the FTC-203 study. Subjects participating in this rollover protocol will receive emtricitabine, for as long as they continue to meet specific virologic criteria and until they withdraw from study or emtricitabine is approved in the country of residence.
Condition | Intervention | Phase |
---|---|---|
HIV-1 Infection |
Drug: FTC |
Phase II |
Study Type: | Interventional |
Study Design: | Non-Randomized, Open Label, Active Control, Single Group Assignment |
Official Title: | A Rollover Protocol to Provide Subjects Completing the FTC-203 Study in South Africa With Continued Access to Emtricitabine |
Enrollment: | 49 |
Study Start Date: | December 2005 |
Estimated Study Completion Date: | December 2020 |
Estimated Primary Completion Date: | December 2020 (Final data collection date for primary outcome measure) |
FTC capsule 200mg qd
FTC Oral Solution 6mg/kg qd
In addition to access to emtricitabine, the study will collect long-term safety information in subjects receiving emtricitabine in combination with other antiretroviral agents. Data collection during the rollover protocol for safety purposes will be limited to the reporting of adverse events (AEs) that (1) meet the criteria for a serious adverse event (SAE), (2) result in permanent discontinuation of the study drug, emtricitabine, and/or (3) are associated with skin discoloration (hyperpigmentation).
Ages Eligible for Study: | 1 Month to 17 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
South Africa | |
Themba Lethu Clinic, Helen Joseph Hospital, Westdene | |
Johannesburg, South Africa | |
Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital | |
Soweto, South Africa |
Responsible Party: | Gilead Sciences, Inc. ( Elsa Mondou, MD ) |
Study ID Numbers: | GS-US-162-0112 |
Study First Received: | August 26, 2008 |
Last Updated: | August 27, 2008 |
ClinicalTrials.gov Identifier: | NCT00743340 |
Health Authority: | United States: Food and Drug Administration |
HIV-1 infection emtricitabine pediatrics pediatric patients |
Emtricitabine HIV Infections Acquired Immunodeficiency Syndrome |
Anti-Infective Agents Therapeutic Uses Infection Antiviral Agents Pharmacologic Actions |